HaTay Pharmaceutical JSC

HaTay Pharmaceutical JSC EBITDA per Share

The EBITDA per Share of HaTay Pharmaceutical JSC (DHT.VN) as of Nov 2, 2026 is 873.16 VND. In the previous year, EBITDA per Share was 1,783.65 VND — a change of -51.05% (lower).

EBITDA per Share

873.16VND

YoY

-51.05%

Last updated:

EBITDA per Share of HaTay Pharmaceutical JSC is 2024 873.16 VND. EBITDA per Share of HaTay Pharmaceutical JSC was 2023 1,783.65 VND. It decreases by -51.05% lower compared to the previous year.

The HaTay Pharmaceutical JSC EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
5,385.56 VND
Jan 1, 2018
5,134.22 VND
Jan 1, 2019
4,975.95 VND
Jan 1, 2020
1,532.09 VND
Jan 1, 2021
892.21 VND
Jan 1, 2022
1,298.35 VND
Jan 1, 2023
1,783.65 VND
Jan 1, 2024
873.16 VND
The HaTay Pharmaceutical JSC EBITDA per Share history
YEAREBITDA per ShareYoY
873.16VND-51.05%
1,783.65VND+37.38%
1,298.35VND+45.52%
892.21VND-41.77%
1,532.09VND-69.21%
4,975.95VND-3.08%
5,134.22VND-4.67%
5,385.56VND+69.31%
3,180.97VND+28.26%
2,480.19VND+33.67%
1,855.45VND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HaTay Pharmaceutical JSC Stock analysis

What does HaTay Pharmaceutical JSC do? Ha Tay Pharmaceutical JSC generates revenue through the manufacturing, import, and export of pharmaceuticals, cosmetics, and medical equipment. The company sells its products via wholesale and retail channels, targeting healthcare providers, pharmacies, and consumers. It also engages in the production and trading of cosmetic products, supplemental food, and laboratory chemicals, alongside medical equipment and supplies. The firm completed the acquisition of a 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company in 2013, expanding its market presence in pharmaceuticals and medical equipment. The company operates in the pharmaceutical sector, serving healthcare institutions, retail pharmacies, and end consumers. Its revenue streams include the sale of drugs, cosmetics, medical equipment, and related supplies. Additional income comes from supermarket operations, real estate leasing, and vocational training services, though these are secondary to its core pharmaceutical business. Ha Tay Pharmaceutical JSC's primary customers are healthcare providers, pharmacies, and consumers purchasing pharmaceuticals, cosmetics, and medical equipment. The firm's product portfolio spans drugs, vaccines, cosmetic products, supplemental food, and laboratory chemicals, with a focus on manufacturing and trading. The acquisition of the 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company has strengthened its position in the medical equipment market. HaTay Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HaTay Pharmaceutical JSC stock

EBITDA per Share of HaTay Pharmaceutical JSC is 873.16 VND in 2024.

EBITDA per Share of HaTay Pharmaceutical JSC changed from 1,783.65 VND to 873.16 VND, representing a -51.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share HaTay Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — HaTay Pharmaceutical JSC

All Key Metrics — HaTay Pharmaceutical JSC